相似文献
1
Chitosan-based crosslinking for controlled topical drug release in rhinosinusitis.
Int Forum Allergy Rhinol. 2024 Nov;14(11):1802-1805. doi: 10.1002/alr.23413. Epub 2024 Jul 11.
2
Designing of biocompatible and biodegradable chitosan based crosslinked hydrogel for in vitro release of encapsulated povidone-iodine: A clinical translation.
Int J Biol Macromol. 2020 Dec 1;164:4370-4380. doi: 10.1016/j.ijbiomac.2020.09.031. Epub 2020 Sep 12.
3
Inflammation targeted chitosan-based hydrogel for controlled release of diclofenac sodium.
Int J Biol Macromol. 2020 Nov 1;162:175-187. doi: 10.1016/j.ijbiomac.2020.06.133. Epub 2020 Jun 17.
4
Optimizing the chitosan-cellulose based drug delivery system for controlling the ciprofloxacin release versus organic/inorganic crosslinker, characterization and kinetic study.
Int J Biol Macromol. 2020 Dec 15;165(Pt A):1496-1506. doi: 10.1016/j.ijbiomac.2020.10.047. Epub 2020 Oct 13.
5
Chemical cross-linking: A feasible approach to prolong doxylamine/pyridoxine release from spray-dried chitosan microspheres.
Eur J Pharm Sci. 2018 Oct 15;123:387-394. doi: 10.1016/j.ejps.2018.07.059. Epub 2018 Aug 2.
6
In vitro evaluation of sustained ciprofloxacin release from κ-carrageenan-crosslinked chitosan/hydroxyapatite hydrogel nanocomposites.
Int J Biol Macromol. 2019 Apr 1;126:443-453. doi: 10.1016/j.ijbiomac.2018.12.240. Epub 2018 Dec 27.
7
Chitosan-genipin microspheres for the controlled release of drugs: clarithromycin, tramadol and heparin.
Mar Drugs. 2010 May 26;8(6):1750-62. doi: 10.3390/md8061750.
8
Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
Int J Pharm. 2011 Jul 15;413(1-2):229-36. doi: 10.1016/j.ijpharm.2011.04.031. Epub 2011 Apr 21.
9
Controlled release and antioxidant activity of chitosan or its glucosamine water-soluble derivative microcapsules loaded with quercetin.
Int J Biol Macromol. 2018 Jun;112:399-404. doi: 10.1016/j.ijbiomac.2018.01.085. Epub 2018 Feb 5.
10
Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system.
Int J Pharm. 2007 May 24;336(2):329-37. doi: 10.1016/j.ijpharm.2006.12.019. Epub 2006 Dec 20.
本文引用的文献
1
Use of Off-Label Nasal Steroid Irrigations in Long-Term Management of Chronic Rhinosinusitis.
Ear Nose Throat J. 2021 Jun;100(5):329-334. doi: 10.1177/0145561321998521. Epub 2021 Mar 8.
2
In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms.
Int Forum Allergy Rhinol. 2020 Jan;10(1):121-127. doi: 10.1002/alr.22475. Epub 2019 Nov 6.
3
Topical therapies for management of chronic rhinosinusitis: steroid implants.
Int Forum Allergy Rhinol. 2019 May;9(S1):S22-S26. doi: 10.1002/alr.22344.
4
In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms.
Int Forum Allergy Rhinol. 2019 May;9(5):486-492. doi: 10.1002/alr.22285. Epub 2019 Jan 31.
5
Chitosan-Based Nanomaterials for Drug Delivery.
Molecules. 2018 Oct 16;23(10):2661. doi: 10.3390/molecules23102661.
6
Infectious Chronic Rhinosinusitis.
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):584-9. doi: 10.1016/j.jaip.2016.04.008.
7
Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy.
Eur J Pharm Biopharm. 2015 Oct;96:65-75. doi: 10.1016/j.ejpb.2015.07.010. Epub 2015 Jul 17.
8
Use of topical nasal therapies in the management of chronic rhinosinusitis.
Laryngoscope. 2013 Oct;123(10):2347-59. doi: 10.1002/lary.24066. Epub 2013 Apr 1.
9
Chronic rhinosinusitis as a multifactorial inflammatory disorder.
Curr Infect Dis Rep. 2011 Apr;13(2):159-68. doi: 10.1007/s11908-011-0166-z.
Zotero 插件